Abstract 2371: Dietary Supplementation with Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Prevents Activation of Inflammation and Development of Left Ventricular Dysfunction Induced by Chronic Pressure Overload
Activation of inflammatory pathways plays a role in the development and progression of heart failure, and recent studies suggest that supplementation with EPA and DHA from fish oil exerts anti-inflammatory effects. We evaluated the effects of fish oil enriched with EPA + DHA on inflammation and the development of left ventricle pathology in response to chronic arterial pressure overload. Rats were fed a standard chow or diets supplemented with EPA + DHA at 0.7%, 2.3% or 7% of the total energy intake, underwent either sham surgery or abdominal aorta banding, and were maintained for 12 wks (n = 10 –11 rats/group). Aortic banding with standard chow significantly increased LV mass (39%), and LV end systolic (101%) and end diastolic (29%) volumes, and increased serum TNFα and urine thromboxane B2 (see Figure⇓) and 6-keto prostaglandin F1. Supplementation with EPA + DHA caused a dose dependent increase in EPA and DHA, and a decrease in arachadonic acid content (the precursor of thromboxane B2 and 6-keto prostaglandin F1) in cardiac phospholipids. EPA + DHA prevented inflammation as seen in a dramatic decrease in urinary thromboxane B2 and 6-keto prostaglandin F1, and serum TNFα compared to aortic banded rats on standard chow (p < 0.01). EPA + DHA supplementation completely prevented increases in LV end diastolic and systolic volumes (p < 0.01) despite no effect on LV mass or blood pressure. In conclusion, EPA + DHA prevented activation of inflammation in response to pressure overload, and the subsequent development of LV remodeling and dysfunction, suggesting that treatment with EPA + DHA may be clinically effective for preventing the development and progression of heart failure.
This research has received full or partial funding support from the American Heart Association, AHA Mid-Atlantic Affiliate (Maryland, North Carolina, South Carolina, Virginia & Washington, DC).